| 000 | 01472 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250516111301.0 | ||
| 264 | 0 | _c20130520 | |
| 008 | 201305s 0 0 eng d | ||
| 022 | _a1534-6307 | ||
| 024 | 7 |
_a10.1007/s11926-012-0290-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSilva, Francisco | |
| 245 | 0 | 0 |
_aTNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis. _h[electronic resource] |
| 260 |
_bCurrent rheumatology reports _cDec 2012 |
||
| 300 |
_a501-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 |
_aAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis _xdrug therapy |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 |
_aGranulomatosis with Polyangiitis _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadverse effects |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 |
_aNeoplasms _xepidemiology |
| 650 | 0 | 4 | _aReceptors, Tumor Necrosis Factor |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aCisternas, Marcela | |
| 700 | 1 | _aSpecks, Ulrich | |
| 773 | 0 |
_tCurrent rheumatology reports _gvol. 14 _gno. 6 _gp. 501-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11926-012-0290-2 _zAvailable from publisher's website |
| 999 |
_c22084211 _d22084211 |
||